Kaposi's sarcoma: New treatment modalities

Dermatologic Clinics

Volumn 18, Issue 1, 2000, Pages 169-175

  Gascón, Pere ^a,b   Schwartz, Robert A ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ALITRETINOIN; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTHRACYCLINE; ANTIRETROVIRUS AGENT; BASIC FIBROBLAST GROWTH FACTOR; BLEOMYCIN; CHORIONIC GONADOTROPIN; COLLAGEN; DAUNORUBICIN; DIPEPTIDE; DOXORUBICIN; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; IM 862; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 6; LIPOSOME; ONCOSTATIN M; PACLITAXEL; RETINOIC ACID; TECOGALAN; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VINBLASTINE; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BONE MARROW TOXICITY; CLINICAL TRIAL; HUMAN; KAPOSI SARCOMA; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0033982272     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(05)70157-1     Document Type: Article

References (34)

1. D. Aboulafia D. Norris R.J. Grossman Interim analysis of Phase II study (Protocol L1057-280) of panretin capsules for AIDS related Kaposi's sarcoma J Acquir Immune Defic Syndr Hum Retrovirol 4 1998 A24
2. T. Boehm J. Folkman T. Brower Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance Nature 390 1997 404 407
3. Bodsworth N, for The International Panretin Gel KS Study Group: North American phase III study (protocol L1057T-31) of Panretin gel (LGD 1057, ALRT 1057) for cutaneous AIDS-related Kaposi's sarcoma. Presented at the 12th World AIDS Conference, Geneva, Switzerland, 1998
4. Conant M, for The International and North American Panretin Gel KS Study Groups: Topical aliretinoid gel as treatment for cutaneous lesions of AIDS-related Kaposi's sarcoma: Interim results of an international, placebo-controlled trial (Alrt 1057-503). Presented at the 12th World AIDS Conference, Geneve, Switzerland, 1998
5. Dezube B.J. von Roenn J.H. J. Holden-Wiltse Fumagillin analog in the treatment of Kaposi's sarcoma: A phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team J Clin Oncol 16 1998 1444 1449
6. B. Ensoli S. Nakamura S.Z. Salahuddin AIDS-Kaposi's sarcoma derived cells express cytokines with autocrine and paracrine growth effects Science 243 1989 223 226
7. B. Ensoli R. Gendelman P. Markham Synergy between basic fibroblast growth factor and HIV-1 tat protein in induction of Kaposi's sarcoma Nature 371 1994 674 680
8. A. Freidman-Kein B. Dezube J. Lee Oral 9-cis-retinoid acid in AIDS-related-Kaposi's sarcoma. AIDS malignancy consortium study 002 J Acquir Immune Defic Syndr Hum Retrovirol 4 1998 A24
9. A. Gabizon Selective tumor localization and improved therapeutic index of anthracyclines in long circulating liposomes Cancer Res 52 1992 1891 1896
10. P.S. Gill B. Akil P. Colleti Pulmonary Kaposi's sarcoma. Clinical findings and results of therapy Am J Med 87 1989 57 61
11. Gill PS, Kidane S, Tulpule A, et al: A phase I study of DS-4152, a novel angiogenesis inhibitor in the treatment of AIDS-related Kaposi's sarcoma. Presented at the Eighth NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, 1994
12. P.S. Gill B.M. Espina S. Cabriales A phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin (Daunoxome) in the treatment of advanced AIDS-related Kaposi's sarcoma J Clin Oncol 13 1995 996 1003
13. P.S. Gill J. Wenrz D.T. Scadden Randomized Phase II trial of liposomal daunorubicin (DaunoXome) versus doxorubicin, bleomycin, vincristine (ABV) in AIDS related Kaposi's sarcoma J Clin Oncol 14 1996 2353 2364
14. P.S. Gill A. Tulpule J. Hadjenberg Paclitaxel (Taxol) is highly effective in the treatment of patients with advanced AIDS-related Kaposi's sarcoma J Acquir Immune Def Syndr Hum Retrovirol 14 1997 A35
15. P.S. Gill T. McLaughlin B.M. Espina Phase I study of a preparation of human chorionic gonadotropin given subcutaneously to patients with AIDS-related Kaposi's sarcoma J Natl Cancer Inst 89 1997 1797 1802
16. P.S. Gill M.U. Rarick J.A. McCutchan Systemic treatment of AIDS-related Kaposi's sarcoma in AIDS Trials Group (ACTG) Trials J Acquir Immune Defic Syndr Hum Retrovirol 17 1998 A39
17. J.E. Groopman M.S. Gotlieb J. Goodman Recombinant alpha-2 interferon for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome Ann Intern Med 100 1984 671 674
18. D.H. Kedes E. Operskalski M. Busch The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma associated herpesvirus): Distribution of infection in KS risk groups and evidence for sexual transmission Nat Med 2 1996 918 924
19. E. Klein R.A. Schwartz Y. Laor Treatment of Kaposi's sarcoma with vinblastine Cancer 45 1980 427 431
20. B.R. Leigh P.A. Burke G.T. Wurz Toremifene reverses doxorubicin resistance in Kaposi's sarcoma cells J Clin Oncol 18 1999 218a
21. R. Litle L. Welles K. Wyvill Preliminary results of a phase II study of oral thalidomide in patients with AIDS-related Kaposi's sarcoma J Acquir Immune Defic Hum Retrovirol 4 1998 A16
22. Y. Lunardi-Iskandar J.L. Bryant R.A. Zeman Tumorigenesis and metastasis of neoplastic Kaposi's sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone Nature 375 1995 64 69
23. R. Massod S.R. Husain A. Rahman Potentiation of cytotoxicity of Kaposi's sarcoma related to immunodeficiency syndrome (AIDS) by liposome encapsulated doxorubicin AIDS Res Hum Retroviruses 8 1993 741 745
24. R. Masood J. Cai T. Zheng Vascular endothelial growth factor (Vascular permeability factor (VEGF/VPF) is an autocrine growth factor for AIDS-KS Proc Natl Acad Sci U S A 94 1997 979 984
25. S. Nagpal J. Cai T. Zheng Retinoid antagonism of NF-IL-6: Insight into the mechanism of anti-proliferative effects of retinoids in Kaposi's sarcoma Mol Cell Biol 17 1997 4159 4168
26. D.W. Northfelt B.J. Dezube J.A. Thommes Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy J Clin Oncol 15 1997 653 659
27. M.S. O'Reilly L. Holmgren Y. Shing Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastasis by a Lewis lung carcinoma Cell 79 1994 315 328
28. M.S. O'Reilly T. Boehm Y. Shing Endostatin: Endogenous inhibitor of angiogenesis and tumor growth Cell 88 1997 227 285
29. J.M. Pluda R. Wyvill J. Litle A pilot dose-finding study of Interleukin 12 (IL-12) administered to patients with AIDS-associated Kaposi's sarcoma J Clin Oncol 18 1999 547a
30. C.S. Rabkin M.A. Testa M. Fischl Declining incidence of Kaposi's sarcoma in AIDS Trials Group (ACTG) Trials [abstract] J Acquir Immune Defic Syndr Hum Retrovirol 17 1998 A39
31. M.W. Saville J. Leitzau J.M. Pluda Treatment of HIV-associated Kaposi's sarcoma with paclitaxel Lancet 346 1995 26 28
32. R.A. Schwartz Kaposi's sarcoma: Advances and perspectives J Am Acad Dermatol 34 1996 804 814
33. A. Tulpule B.M. Espina S. Cabriales IM862 Nasal Solution is an active anti-angiogenic agent in the treatment of AIDS-related Kaposi's sarcoma J Clin Oncol 18 1999 535a
34. J. Vogel S.H. Hinrichs R.K. Reynolds The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice Nature 335 1988 606 611